BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.71 CNY | +3.82% |
|
+19.12% | -12.26% |
| Sales 2021 | 1.05B 145M 199M | Sales 2022 | 1.02B 141M 192M | Capitalization | 9.54B 1.32B 1.8B |
|---|---|---|---|---|---|
| Net income 2021 | 244M 33.71M 46.13M | Net income 2022 | 240M 33.16M 45.38M | EV / Sales 2021 | 14.8 x |
| Net Debt 2021 | 565M 78.04M 107M | Net Debt 2022 | 791M 109M 150M | EV / Sales 2022 | 10.2 x |
| P/E ratio 2021 |
61.2
x | P/E ratio 2022 |
38.9
x | Employees | 1,128 |
| Yield 2021 |
0.33% | Yield 2022 |
0.51% | Free-Float | 48.25% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.82% | ||
| 1 week | +19.12% | ||
| Current month | +4.88% | ||
| 1 month | +4.88% | ||
| 3 months | +14.72% | ||
| 6 months | -25.66% | ||
| Current year | -12.26% |
1 week
26.30
30.82
1 month
24.4330.82
Current year
19.6334.90
1 year
17.8146.88
3 years
17.1048.49
5 years
17.1072.43
10 years
17.1072.43
| Managers | Title | Age | Since |
|---|---|---|---|
Jian Dong Yuan
CEO | Chief Executive Officer | 54 | 01-10-25 |
Yuan Lai Zou
DFI | Director of Finance/CFO | 53 | 10-12-31 |
Fan Hang
BRD | Director/Board Member | 38 | 05-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jian Dong Yuan
CEO | Chief Executive Officer | 54 | 01-10-25 |
Simon Lü
BRD | Director/Board Member | 56 | 17-05-12 |
Kai Li
PRN | Corporate Officer/Principal | 48 | 06-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.43% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 30.71 | +3.82% | 12,913,130 |
| 24-04-26 | 29.58 | +3.72% | 12,162,740 |
| 24-04-25 | 28.52 | +4.51% | 11,525,650 |
| 24-04-24 | 27.29 | +3.18% | 5,395,480 |
| 24-04-23 | 26.45 | +2.60% | 4,992,646 |
End-of-day quote Shanghai S.E., April 28, 2024
More quotes
BrightGene Bio-Medical Technology Co Ltd is a China-based company mainly engaged in the research, development and production of generic drugs and original new drugs. The Company's main products include antifungal active pharmaceutical ingredients (APIs), antiviral APIs, immunosuppressive APIs, and other APIs and preparations. The Company's generic drugs mainly include entecavir, caspofungin, micafungin, posaconazole, everolimus and fondaparinux sodium. The Company mainly conducts its businesses in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -12.26% | 1.79B | |
| +26.47% | 664B | |
| +30.35% | 567B | |
| -6.33% | 354B | |
| +19.35% | 330B | |
| +4.23% | 286B | |
| +14.28% | 234B | |
| +4.96% | 199B | |
| -10.10% | 196B | |
| -4.04% | 148B |
- Stock Market
- Equities
- 688166 Stock
